Research programme: selective androgen receptor inhibitors - GTx

Drug Profile

Research programme: selective androgen receptor inhibitors - GTx

Alternative Names: GTx-SARD; SARD - GTx; Selective androgen receptor degrader - GTx

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Tennessee Research Foundation
  • Developer GTx
  • Class Antiandrogens; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Prostate cancer presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 15 Mar 2017 GTx plans a phase I trial for Prostate cancer (castration-resistant) in USA
  • 15 Mar 2017 GTx has patent protection for selective androgen receptor inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top